GlassScriptPhysician profile
Ann D Chauffe
NPI 1306039201
$49,402.63
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,615 · 2020: $3,992 · 2021: $25K · 2022: $2,775 · 2023: $9,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,652 · Consulting Fee: $3,380 · Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,652.43 |
| Consulting Fee | $3,380.00 |
| Food and Beverage | $991.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35,166.05 | 2020-2023 | Ofev |
| Regeneron Pharmaceuticals, INC. | $7,234.07 | 2019 | |
| Ucb, INC. | $3,594.01 | 2019-2023 | |
| Argenx US, INC. | $1,570.74 | 2023 | Vyvgart |
| Pfizer INC. | $247.29 | 2019 | |
| Mallinckrodt Enterprises LLC | $202.70 | 2019 | |
| Celgene Corporation | $189.73 | 2019 | |
| Amgen INC. | $144.77 | 2019-2021 | |
| Radius Health, INC. | $127.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $125.28 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $122.56 | 2023 | |
| Lilly USA, LLC | $96.72 | 2019 | |
| Horizon Therapeutics Plc | $79.67 | 2019-2020 | |
| Genentech USA, INC. | $76.87 | 2019-2021 | |
| Abbvie INC. | $72.35 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $60.08 | 2019-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $52.90 | 2019 | |
| Medexus Pharma, INC. | $52.39 | 2019 | |
| Mallinckrodt Hospital Products INC. | $46.27 | 2020 | |
| Emd Serono, INC. | $38.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.66 | 2021 | |
| Antares Pharma, INC. | $25.76 | 2019 | |
| Shire North American Group INC | $17.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Chauffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.